Cited 5 times in
Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이병완 | - |
dc.date.accessioned | 2022-05-09T17:01:14Z | - |
dc.date.available | 2022-05-09T17:01:14Z | - |
dc.date.issued | 2022-04 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/188336 | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | DIABETES OBESITY & METABOLISM | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Diabetes Mellitus, Type 2* / complications | - |
dc.subject.MESH | Diabetes Mellitus, Type 2* / drug therapy | - |
dc.subject.MESH | Dipeptidyl-Peptidase IV Inhibitors* / adverse effects | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver | - |
dc.subject.MESH | Non-alcoholic Fatty Liver Disease* / complications | - |
dc.subject.MESH | Non-alcoholic Fatty Liver Disease* / drug therapy | - |
dc.subject.MESH | Piperazines | - |
dc.title | Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Eugene Han | - |
dc.contributor.googleauthor | Ji Hye Huh | - |
dc.contributor.googleauthor | Eun Y Lee | - |
dc.contributor.googleauthor | Ji C Bae | - |
dc.contributor.googleauthor | Sung W Chun | - |
dc.contributor.googleauthor | Sung H Yu | - |
dc.contributor.googleauthor | Soo H Kwak | - |
dc.contributor.googleauthor | Kyong S Park | - |
dc.contributor.googleauthor | Byung-Wan Lee | - |
dc.identifier.doi | 10.1111/dom.14623 | - |
dc.contributor.localId | A02796 | - |
dc.relation.journalcode | J00722 | - |
dc.identifier.eissn | 1463-1326 | - |
dc.identifier.pmid | 34918436 | - |
dc.identifier.url | https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14623 | - |
dc.subject.keyword | dipeptidyl peptidase-4 inhibitor | - |
dc.subject.keyword | evogliptin | - |
dc.subject.keyword | magnetic resonance imaging-derived proton density fat fraction | - |
dc.subject.keyword | non-alcoholic fatty liver disease | - |
dc.subject.keyword | pioglitazone | - |
dc.subject.keyword | type 2 diabetes | - |
dc.contributor.alternativeName | Lee, Byung Wan | - |
dc.contributor.affiliatedAuthor | 이병완 | - |
dc.citation.volume | 24 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 752 | - |
dc.citation.endPage | 756 | - |
dc.identifier.bibliographicCitation | DIABETES OBESITY & METABOLISM, Vol.24(4) : 752-756, 2022-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.